Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Summit Therapeutics Inc. (SMMT)
USD15.20
-0.28 (-1.78%)
US NASDAQ Healthcare Biotechnology
Address
One Broadway 2142
Cambridge, MA, US
Cambridge, MA, US
CEO
Robert W. Duggan
Website
summittxinc.com
IPO
2015-03-05
CIK 1599298 ISIN US86627T1088
Description
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
News Sentiment (7d)
Based on only 2 articles — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD15.20
-0.28 (-1.78%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
5M
Beta
-1.26
Float Shares
107.26M
Free Float %
13.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.55% | +5.75% | -3.66% | +29.53% | +0.64% | +8.35% | -24.98% | +1,001.74% | +246.44% | +130.82% | +85.97% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (21 ratings, all time)
Buy
Price Targets & DCF
Current price
15.20
Low
16.00
+5.3%
Consensus
19.00
+25.0%
Median
18.00
+18.5%
High
23.00
+51.4%
DCF (Unlevered)
0.25
-98.4%
DCF (Levered)
0.28
-98.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
71% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 11 | 0 |
| Hold | 4 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 2 |
19.50
+28.3%
|
| Last Quarter | 3 |
23.00
+51.4%
|
| Last Year | 9 |
24.11
+58.7%
|
| All Time | 20 |
28.70
+88.9%
|
Quality scores
Altman Z-Score
72.79
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-476.0% Q1'26: -244.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +3,142.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+4.1% Q1'26: +5.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.01× Q1'26: -0.02× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 9 Rev. Ana. 8 EPS Ana. |
Dec 2027 10 Rev. Ana. 8 EPS Ana. |
Dec 2028 12 Rev. Ana. 6 EPS Ana. |
Dec 2029 11 Rev. Ana. 4 EPS Ana. |
Dec 2030 6 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.84M
est: 2.82M (-34.5%)
|
1.89M
est: 2.10M (-10.2%)
|
1.28M
est: 1.96M (-34.7%)
|
2.38M
est: 35.88M (-93.4%)
|
14.17M
est: 73.68M (-80.8%)
|
57.09M
est: 19.43M (+193.9%)
|
611.9K
est: 19.43M (-96.9%)
|
628.9K
est: 19.16M (-96.7%)
|
1.34M
est: 1.60M (-16.4%)
|
—
est: 966.0K (-100.0%)
|
—
est: 12.31M (-100.0%)
|
—
est: 42.76M (-100.0%)
|
7.25M
2.59M – 14.01M
-83.0% YoY
|
100.64M
63.05M – 138.46M
+1,287.9% YoY
|
931.98M
895.58M – 968.38M
+826.1% YoY
|
2.44B
1.49B – 3.44B
+162.1% YoY
|
4.35B
2.65B – 6.13B
+78.0% YoY
|
| EBITDA |
-6.68M
est: -563.4K (-1,086.1%)
|
-12.20M
est: -420.4K (-2,801.7%)
|
-20.30M
est: -392.2K (-5,075.4%)
|
-24.80M
est: -7.18M (-245.6%)
|
-26.34M
est: -14.74M (-78.7%)
|
11.66M
est: -3.89M (+400.0%)
|
-21.56M
est: -3.89M (-455.0%)
|
-37.13M
est: -3.83M (-869.3%)
|
-62.74M
est: -320.0K (-19,505.0%)
|
-69.45M
est: -193.2K (-35,847.9%)
|
-168.46M
est: 2.46M (-6,942.2%)
|
-1.08B
est: 8.55M (-12,722.7%)
|
1.45M
518.9K – 2.80M
-83.0% YoY
|
20.13M
12.61M – 27.69M
+1,287.9% YoY
|
186.40M
179.12M – 193.68M
+826.1% YoY
|
488.58M
298.22M – 688.50M
+162.1% YoY
|
869.59M
530.77M – 1.23B
+78.0% YoY
|
| EBIT |
-6.71M
est: -563.4K (-1,090.7%)
|
-12.23M
est: -420.4K (-2,809.5%)
|
-20.35M
est: -392.2K (-5,087.7%)
|
-24.85M
est: -7.18M (-246.4%)
|
-26.74M
est: -14.74M (-81.5%)
|
9.70M
est: -3.89M (+349.7%)
|
-22.62M
est: -3.89M (-482.3%)
|
-38.27M
est: -3.83M (-898.9%)
|
-63.73M
est: -320.0K (-19,816.3%)
|
-69.61M
est: -193.2K (-35,928.3%)
|
-168.53M
est: 2.46M (-6,945.1%)
|
-1.08B
est: 8.55M (-12,724.4%)
|
1.45M
518.9K – 2.80M
-83.0% YoY
|
20.13M
12.61M – 27.69M
+1,287.9% YoY
|
186.40M
179.12M – 193.68M
+826.1% YoY
|
488.58M
298.22M – 688.50M
+162.1% YoY
|
869.59M
530.77M – 1.23B
+78.0% YoY
|
| Net Income |
-6.09M
est: -1.66B (+99.6%)
|
-11.38M
est: -1.55B (+99.3%)
|
-20.14M
est: -1.59B (+98.7%)
|
-21.37M
est: -150.71M (+85.8%)
|
-20.16M
est: 351.47M (-105.7%)
|
10.87M
est: -245.43M (+104.4%)
|
-23.99M
est: -245.43M (+90.2%)
|
-38.53M
est: -574.83M (+93.3%)
|
-65.52M
est: -689.80M (+90.5%)
|
-482.37M
est: -431.13M (-11.9%)
|
-176.77M
est: -283.79M (+37.7%)
|
-1.08B
est: -738.96M (-46.1%)
|
-917.42M
-1.00B – -727.03M
-24.1% YoY
|
-897.50M
-1.02B – -754.26M
+2.2% YoY
|
-49.79M
-3.34B – 6.14B
+94.5% YoY
|
554.13M
273.45M – 848.88M
+1,212.8% YoY
|
1.56B
769.92M – 2.39B
+181.6% YoY
|
| SGA |
1.94M
est: 42.44M (-95.4%)
|
3.70M
est: 31.67M (-88.3%)
|
4.77M
est: 29.54M (-83.9%)
|
8.28M
est: 540.48M (-98.5%)
|
11.94M
est: 1.11B (-98.9%)
|
17.01M
est: 292.65M (-94.2%)
|
9.29M
est: 292.65M (-96.8%)
|
14.06M
est: 288.59M (-95.1%)
|
17.46M
est: 24.10M (-27.6%)
|
23.74M
est: 14.55M (+63.1%)
|
48.35M
est: 132.91M (-63.6%)
|
556.70M
est: 461.64M (+20.6%)
|
78.29M
28.01M – 151.26M
-83.0% YoY
|
1.09B
680.73M – 1.49B
+1,287.9% YoY
|
10.06B
9.67B – 10.46B
+826.1% YoY
|
26.38B
16.10B – 37.17B
+162.1% YoY
|
46.95B
28.65B – 66.15B
+78.0% YoY
|
| EPS |
-0.30
est: -2.31 (+87.0%)
|
-0.29
est: -2.15 (+86.5%)
|
-0.34
est: -2.21 (+84.6%)
|
-0.35
est: -0.21 (-66.9%)
|
-0.31
est: 0.49 (-163.4%)
|
0.11
est: -0.34 (+132.2%)
|
-0.73
est: -0.34 (-113.7%)
|
-0.55
est: -0.80 (+31.3%)
|
-0.71
est: -0.96 (+26.0%)
|
-0.78
est: -0.60 (-30.0%)
|
-0.25
est: -0.38 (+34.1%)
|
-1.44
est: -1.11 (-29.3%)
|
-1.10
-1.34 – -0.97
+0.8% YoY
|
-1.12
-1.36 – -1.01
-1.4% YoY
|
-0.29
-4.47 – 8.21
+74.5% YoY
|
0.74
0.37 – 1.14
+359.8% YoY
|
2.09
1.03 – 3.20
+181.6% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-04 | HC Wainwright & Co. | Buy | Buy | Maintain |
| 2026-05-01 | Piper Sandler | Neutral | Neutral | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-384.05M
OE per share TTM
-0.51
Owner's Yield
-2.65%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
1,153.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
62
Total invested
104.57M
Insider transactions (90d)
0
Beneficial owners (>5%)
9
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ROBERT W. DUGGAN | 46.21M | 64.89% | — | — | 46.21M | 10.00 | IN | — | 2020-09-28 | ↗ |
| 2 | Polar Capital Holdings Plc | 5.80M | 7.05% | — | 5.80M | — | — | HC | United Kingdom | 2021-02-16 | ↗ |
| 3 | Polar Capital LLP | 5.80M | 7.05% | — | 5.80M | — | — | IA | United Kingdom | 2021-02-16 | ↗ |
| 4 | MAHKAM ZANGANEH | 5.33M | 7.80% | — | — | 489.8K | 4.84M | IN | — | 2020-09-28 | ↗ |
| 5 | Point72 Asset Management, L.P. | 3.86M | 6.60% | — | 3.86M | — | — | PN | Delaware | 2015-03-11 | ↗ |
| 6 | Point72 Capital Advisors, Inc. | 3.86M | 6.60% | — | 3.86M | — | — | CO | Delaware | 2015-03-11 | ↗ |
| 7 | Steven A. Cohen | 3.86M | 6.60% | — | 3.86M | — | — | IN | Delaware | 2015-03-11 | ↗ |
| 8 | MAHKAM ZANGANEH REVOCABLE TRUST | 2.42M | 3.58% | — | — | — | 2.42M | OO | — | 2020-09-28 | ↗ |
| 9 | SHAUN ZANGANEH IRREVOCABLE TRUST | 2.42M | 3.58% | — | — | — | 2.42M | OO | — | 2020-09-28 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
62
-160 vs prev Q
New positions
16
Closed positions
166
Increased
37
Reduced
12
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BAKER BROS. ADVISORS LP | 36.39M +2.7M (+7.9%) | 636.48M -60.2M (-8.6%) | 4.90% +0.354 pp | 3.73% -1.308 pp | USD12.64 +38.4% | 7 qtrs — |
| 2 | FMR LLC | 13.36M +4.4M (+49.8%) | 233.68M +49.4M (+26.8%) | 1.80% +0.596 pp | 0.01% +0.002 pp | USD10.79 +62.1% | 11 qtrs — |
| 3 | VANGUARD GROUP INC | 11.18M -202.5K (-1.8%) | 195.49M -39.6M (-16.9%) | 1.50% -0.029 pp | 0.00% -0.001 pp | USD11.08 +57.9% | 21 qtrs — |
| 4 | PRICE T ROWE ASSOCIATES INC /MD/ | 9.37M +4.8M (+106.5%) | 163.91M +70.1M (+74.8%) | 1.26% +0.649 pp | 0.02% +0.008 pp | USD17.46 +0.2% | 11 qtrs — |
| 5 | BLACKROCK, INC. | 9.36M +2.0M (+27.1%) | 163.74M +11.6M (+7.6%) | 1.26% +0.268 pp | 0.00% +0.000 pp | USD20.77 -15.8% | 6 qtrs — |
| 6 | STATE STREET CORP | 6.64M +274.4K (+4.3%) | 116.07M -15.4M (-11.7%) | 0.89% +0.036 pp | 0.00% -0.001 pp | USD13.47 +29.8% | 13 qtrs — |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 3.15M +14.7K (+0.5%) | 55.06M -9.7M (-14.9%) | 0.42% +0.002 pp | 0.00% -0.001 pp | USD5.20 +236.3% | 22 qtrs — |
| 8 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.80M +411.0K (+29.5%) | 31.53M +2.8M (+9.7%) | 0.24% +0.055 pp | 0.00% +0.000 pp | USD19.37 -9.7% | 13 qtrs — |
| 9 | POLYMER CAPITAL MANAGEMENT (HK) LTD | 1.42M +603.9K (+73.9%) | 24.86M +8.0M (+47.2%) | 0.19% +0.081 pp | 3.54% +1.208 pp | USD18.96 -7.8% | 5 qtrs — |
| 10 | PICTET ASSET MANAGEMENT HOLDING SA | 1.38M -220.4K (-13.7%) | 24.38M -9.1M (-27.2%) | 0.19% -0.030 pp | 0.02% -0.009 pp | USD16.00 +9.3% | 8 qtrs — |
| 11 | NORGES BANK | 1.37M +1.4M (+100.0%) | 24.03M +24.0M (+100.0%) | 0.18% +0.185 pp | 0.00% +0.003 pp | USD17.49 +0.0% | 1 qtrs NEW |
| 12 | APEIRON CAPITAL LTD | 1.31M -1.7K (-0.1%) | 22.90M -4.2M (-15.5%) | 0.18% 0.000 pp | 26.48% +13.611 pp | USD21.23 -17.6% | 3 qtrs — |
| 13 | TD ASSET MANAGEMENT INC | 1.21M +667.7K (+124.2%) | 21.08M +10.0M (+89.8%) | 0.16% +0.090 pp | 0.02% +0.008 pp | USD17.36 +0.7% | 7 qtrs — |
| 14 | ABRDN PLC | 927.2K -212.4K (-18.6%) | 16.22M -7.3M (-31.1%) | 0.12% -0.029 pp | 0.03% -0.012 pp | USD21.42 -18.3% | 6 qtrs — |
| 15 | MORGAN STANLEY | 926.6K -1.0M (-51.9%) | 16.21M -23.6M (-59.3%) | 0.12% -0.135 pp | 0.00% -0.001 pp | USD18.16 -3.7% | 22 qtrs — |
| 16 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 892.6K +16.2K (+1.9%) | 15.61M -2.5M (-13.8%) | 0.12% +0.002 pp | 0.00% -0.001 pp | USD9.52 +83.7% | 13 qtrs — |
| 17 | UBS GROUP AG | 870.7K -408.1K (-31.9%) | 15.23M -11.2M (-42.4%) | 0.12% -0.055 pp | 0.00% -0.002 pp | USD18.43 -5.1% | 22 qtrs — |
| 18 | SQUAREPOINT OPS LLC | 715.4K +605.6K (+551.4%) | 12.51M +10.2M (+451.5%) | 0.10% +0.081 pp | 0.01% +0.011 pp | USD18.07 -3.2% | 8 qtrs — |
| 19 | ROCK SPRINGS CAPITAL MANAGEMENT LP | 710.0K +— (+0.0%) | 12.42M -2.3M (-15.3%) | 0.10% 0.000 pp | 0.64% -0.220 pp | USD21.85 -20.0% | 6 qtrs — |
| 20 | TWO SIGMA INVESTMENTS, LP | 578.2K +553.2K (+2,210.2%) | 10.11M +9.6M (+1,855.7%) | 0.08% +0.074 pp | 0.01% +0.014 pp | USD17.63 -0.8% | 2 qtrs — |
| 21 | NOMURA HOLDINGS INC | 542.2K -506.7K (-48.3%) | 9.48M -12.2M (-56.2%) | 0.07% -0.068 pp | 0.01% -0.021 pp | USD20.69 -15.5% | 3 qtrs — |
| 22 | CANDRIAM S.C.A. | 540.7K +26.9K (+5.2%) | 9.46M -1.2M (-10.9%) | 0.07% +0.004 pp | 0.05% -0.009 pp | USD21.68 -19.3% | 6 qtrs — |
| 23 | NORTHERN TRUST CORP | 528.5K -17.8K (-3.3%) | 9.24M -2.0M (-18.1%) | 0.07% -0.003 pp | 0.00% 0.000 pp | USD3.22 +443.2% | 19 qtrs — |
| 24 | GOLDMAN SACHS GROUP INC | 485.6K -12.0K (-2.4%) | 8.49M -1.8M (-17.4%) | 0.07% -0.002 pp | 0.00% 0.000 pp | USD14.66 +19.3% | 21 qtrs — |
| 25 | BANK OF AMERICA CORP /DE/ | 477.4K -179.9K (-27.4%) | 8.35M -5.2M (-38.5%) | 0.06% -0.024 pp | 0.00% 0.000 pp | USD13.14 +33.1% | 22 qtrs — |
| 26 | MILLENNIUM MANAGEMENT LLC | 469.0K +348.5K (+289.2%) | 8.20M +5.7M (+229.5%) | 0.06% +0.047 pp | 0.00% +0.002 pp | USD16.09 +8.7% | 7 qtrs — |
| 27 | INVESCO LTD. | 461.3K +35.2K (+8.3%) | 8.07M -734.6K (-8.3%) | 0.06% +0.005 pp | 0.00% 0.000 pp | USD15.78 +10.8% | 12 qtrs — |
| 28 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 441.0K +141.4K (+47.2%) | 7.71M +1.5M (+24.6%) | 0.06% +0.019 pp | 0.01% +0.001 pp | USD15.35 +13.9% | 11 qtrs — |
| 29 | LMR PARTNERS LLP | 424.4K +15.3K (+3.7%) | 7.42M -1.0M (-12.2%) | 0.06% +0.002 pp | 0.01% -0.023 pp | USD19.09 -8.4% | 7 qtrs — |
| 30 | TUDOR INVESTMENT CORP ET AL | 423.1K +75.8K (+21.8%) | 7.40M +225.7K (+3.1%) | 0.06% +0.010 pp | 0.01% +0.001 pp | USD20.09 -12.9% | 2 qtrs — |
| 31 | CITADEL ADVISORS LLC | 417.5K -308.9K (-42.5%) | 7.30M -7.7M (-51.3%) | 0.06% -0.042 pp | 0.00% -0.001 pp | USD20.18 -13.3% | 9 qtrs — |
| 32 | D. E. SHAW & CO., INC. | 415.3K +284.7K (+217.9%) | 7.26M +4.6M (+169.1%) | 0.06% +0.038 pp | 0.00% +0.003 pp | USD18.66 -6.3% | 7 qtrs — |
| 33 | DIMENSIONAL FUND ADVISORS LP | 376.6K +2.0K (+0.5%) | 6.59M -1.2M (-14.9%) | 0.05% +0.000 pp | 0.00% 0.000 pp | USD19.47 -10.2% | 6 qtrs — |
| 34 | QVT FINANCIAL LP | 360.5K +— (+0.0%) | 6.31M -1.1M (-15.3%) | 0.05% 0.000 pp | 0.54% +0.015 pp | USD8.14 +114.9% | 7 qtrs — |
| 35 | SCULPTOR CAPITAL LP | 356.9K +23.4K (+7.0%) | 6.24M -647.9K (-9.4%) | 0.05% +0.003 pp | 0.06% -0.017 pp | USD20.45 -14.5% | 2 qtrs — |
| 36 | AQR CAPITAL MANAGEMENT LLC | 357.9K +170.4K (+90.9%) | 6.19M +2.3M (+59.9%) | 0.05% +0.023 pp | 0.00% +0.001 pp | USD18.48 -5.4% | 7 qtrs — |
| 37 | BANK OF NEW YORK MELLON CORP | 353.8K -13.4K (-3.6%) | 6.19M -1.4M (-18.4%) | 0.05% -0.002 pp | 0.00% 0.000 pp | USD7.71 +126.8% | 13 qtrs — |
| 38 | AFFINITY ASSET ADVISORS, LLC | 350.0K +— (+0.0%) | 6.12M -1.1M (-15.3%) | 0.05% 0.000 pp | 0.35% -0.281 pp | USD20.66 -15.3% | 2 qtrs — |
| 39 | BARCLAYS PLC | 338.4K +88.3K (+35.3%) | 5.92M +440.9K (+8.0%) | 0.05% +0.012 pp | 0.00% +0.000 pp | USD11.27 +55.2% | 16 qtrs — |
| 40 | SKANDINAVISKA ENSKILDA BANKEN AB (PUBL) | 338.4K +— (+0.0%) | 5.91M -1.1M (-15.4%) | 0.05% +0.000 pp | 0.02% -0.004 pp | USD20.25 -13.6% | 5 qtrs — |
| 41 | READYSTATE ASSET MANAGEMENT LP | 306.2K +306.2K (+100.0%) | 5.36M +5.4M (+100.0%) | 0.04% +0.041 pp | 0.22% +0.217 pp | USD17.49 +0.0% | 3 qtrs — |
| 42 | RAFFERTY ASSET MANAGEMENT, LLC | 287.8K -51.4K (-15.1%) | 5.03M -2.0M (-28.2%) | 0.04% -0.007 pp | 0.02% -0.005 pp | USD16.19 +8.0% | 8 qtrs — |
| 43 | JANE STREET GROUP, LLC | 280.0K -129.7K (-31.7%) | 4.90M -3.6M (-42.1%) | 0.04% -0.018 pp | 0.00% -0.001 pp | USD21.15 -17.3% | 6 qtrs — |
| 44 | SCHRODER INVESTMENT MANAGEMENT GROUP | 251.4K +8.8K (+3.6%) | 4.40M -737.0K (-14.4%) | 0.03% +0.001 pp | 0.00% -0.001 pp | USD19.76 -11.5% | 4 qtrs — |
| 45 | CAPTION MANAGEMENT, LLC | 240.0K +34.5K (+16.8%) | 4.20M -48.0K (-1.1%) | 0.03% +0.005 pp | 0.03% -0.004 pp | USD20.54 -14.8% | 4 qtrs — |
| 46 | DEUTSCHE BANK AG\ | 237.8K -32.1K (-11.9%) | 4.16M -1.4M (-25.4%) | 0.03% -0.004 pp | 0.00% -0.001 pp | USD19.28 -9.3% | 11 qtrs — |
| 47 | NUVEEN, LLC | 232.6K +— (+0.0%) | 4.07M -737.5K (-15.3%) | 0.03% +0.000 pp | 0.00% 0.000 pp | USD19.60 -10.8% | 4 qtrs — |
| 48 | VERITION FUND MANAGEMENT LLC | 229.0K +63.4K (+38.3%) | 4.01M +583.7K (+17.1%) | 0.03% +0.009 pp | 0.02% +0.002 pp | USD20.23 -13.5% | 6 qtrs — |
| 49 | WOODLINE PARTNERS LP | 214.5K +— (+0.0%) | 3.75M -680.0K (-15.3%) | 0.03% +0.000 pp | 0.01% -0.006 pp | USD21.19 -17.5% | 3 qtrs — |
| 50 | GRIFFIN ASSET MANAGEMENT, INC. | 195.5K +55.3K (+39.4%) | 3.42M +521.9K (+18.0%) | 0.03% +0.007 pp | 0.37% +0.044 pp | USD19.54 -10.5% | 6 qtrs — |
| 51 | WELLS FARGO & COMPANY/MN | 130.9K -62.0K (-32.1%) | 2.29M -1.7M (-42.6%) | 0.02% -0.008 pp | 0.00% 0.000 pp | USD17.78 -1.6% | 22 qtrs — |
| 52 | CITIGROUP INC | 129.9K -29.9K (-18.7%) | 2.27M -1.0M (-31.2%) | 0.02% -0.004 pp | 0.00% -0.001 pp | USD16.81 +4.0% | 22 qtrs — |
| 53 | RHUMBLINE ADVISERS | 121.3K -1.6K (-1.3%) | 2.12M -417.3K (-16.4%) | 0.02% 0.000 pp | 0.00% 0.000 pp | USD4.09 +327.6% | 11 qtrs — |
| 54 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 121.3K -8.9K (-6.8%) | 2.12M -568.5K (-21.1%) | 0.02% -0.001 pp | 0.16% -0.059 pp | USD11.59 +50.9% | 14 qtrs — |
| 55 | CAPITAL FUND MANAGEMENT S.A. | 113.4K +39.2K (+52.9%) | 1.98M +451.2K (+29.5%) | 0.02% +0.005 pp | 0.01% +0.002 pp | USD19.56 -10.6% | 2 qtrs — |
| 56 | CERITY PARTNERS LLC | 112.9K -1.8K (-1.6%) | 1.97M -394.6K (-16.7%) | 0.02% 0.000 pp | 0.00% -0.001 pp | USD21.40 -18.3% | 6 qtrs — |
| 57 | VOYA INVESTMENT MANAGEMENT LLC | 112.4K -90.2K (-44.5%) | 1.97M -2.2M (-53.0%) | 0.02% -0.012 pp | 0.00% -0.002 pp | USD7.30 +139.6% | 11 qtrs — |
| 58 | PROFUND ADVISORS LLC | 103.8K +33.8K (+48.4%) | 1.81M +370.0K (+25.6%) | 0.01% +0.005 pp | 0.06% +0.008 pp | USD16.56 +5.6% | 8 qtrs — |
| 59 | CENTIVA CAPITAL, LP | 100.0K -111.2K (-52.7%) | 1.75M -2.6M (-59.9%) | 0.01% -0.015 pp | 0.01% -0.027 pp | USD21.25 -17.7% | 3 qtrs — |
| 60 | JEFFERIES FINANCIAL GROUP INC. | 100.0K +85.0K (+566.7%) | 1.75M +1.4M (+464.4%) | 0.01% +0.011 pp | 0.01% +0.008 pp | USD17.97 -2.7% | 2 qtrs — |
| 61 | ILLINOIS MUNICIPAL RETIREMENT FUND | 99.4K +30.7K (+44.7%) | 1.74M +319.1K (+22.5%) | 0.01% +0.004 pp | 0.02% +0.004 pp | USD19.87 -12.0% | 3 qtrs — |
| 62 | HSBC HOLDINGS PLC | 98.8K +98.8K (+100.0%) | 1.72M +1.7M (+100.0%) | 0.01% +0.013 pp | 0.00% +0.001 pp | USD17.49 +0.0% | 1 qtrs NEW |
| 63 | NEOS INVESTMENT MANAGEMENT LLC | 97.2K +16.9K (+21.1%) | 1.70M +41.7K (+2.5%) | 0.01% +0.002 pp | 0.01% -0.003 pp | USD18.82 -7.1% | 5 qtrs — |
| 64 | STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | 96.0K +— (+0.0%) | 1.68M -304.3K (-15.3%) | 0.01% +0.000 pp | 0.00% -0.001 pp | USD16.82 +4.0% | 11 qtrs — |
| 65 | TEMA ETFS LLC | 95.8K +15.5K (+19.3%) | 1.68M +16.6K (+1.0%) | 0.01% +0.002 pp | 0.13% -0.008 pp | USD18.84 -7.2% | 5 qtrs — |
| 66 | BANK OF MONTREAL /CAN/ | 95.4K -2.6K (-2.7%) | 1.67M -357.0K (-17.6%) | 0.01% 0.000 pp | 0.00% 0.000 pp | USD20.48 -14.6% | 9 qtrs — |
| 67 | STATE OF WISCONSIN INVESTMENT BOARD | 92.9K +1.0K (+1.1%) | 1.62M -272.8K (-14.4%) | 0.01% +0.000 pp | 0.00% -0.001 pp | USD20.62 -15.2% | 11 qtrs — |
| 68 | ADAR1 CAPITAL MANAGEMENT, LLC | 91.9K -11.1K (-10.8%) | 1.61M -520.6K (-24.5%) | 0.01% -0.002 pp | 0.12% -0.082 pp | USD20.73 -15.6% | 3 qtrs — |
| 69 | COLONY GROUP, LLC | 88.4K +29.0 (+0.0%) | 1.55M -279.6K (-15.3%) | 0.01% +0.000 pp | 0.00% -0.001 pp | USD21.86 -20.0% | 6 qtrs — |
| 70 | DARK FOREST CAPITAL MANAGEMENT LP | 87.1K -25.1K (-22.4%) | 1.52M -795.2K (-34.3%) | 0.01% -0.003 pp | 0.07% +0.000 pp | USD20.66 -15.3% | 4 qtrs — |
| 71 | AXQ CAPITAL, LP | 81.5K +64.1K (+366.7%) | 1.43M +1.1M (+295.1%) | 0.01% +0.009 pp | 0.32% +0.183 pp | USD18.17 -3.7% | 2 qtrs — |
| 72 | UBS ASSET MANAGEMENT AMERICAS INC | 79.6K +37.0 (+0.0%) | 1.39M -251.7K (-15.3%) | 0.01% +0.000 pp | 0.00% 0.000 pp | USD21.28 -17.8% | 3 qtrs — |
| 73 | SECTORAL ASSET MANAGEMENT INC | 79.6K +5.6K (+7.5%) | 1.39M -137.6K (-9.0%) | 0.01% +0.001 pp | 1.12% +0.172 pp | USD14.74 +18.7% | 12 qtrs — |
| 74 | POLIANTA LTD | 74.7K +— (+0.0%) | 1.31M -237.0K (-15.4%) | 0.01% +0.000 pp | 0.17% -0.465 pp | USD19.55 -10.5% | 4 qtrs — |
| 75 | MARINER, LLC | 73.5K -6.1K (-7.6%) | 1.29M -358.5K (-21.8%) | 0.01% -0.001 pp | 0.00% -0.001 pp | USD20.75 -15.7% | 3 qtrs — |
| 76 | JPMORGAN CHASE & CO | 67.4K -69.2K (-50.7%) | 1.18M -1.6M (-58.2%) | 0.01% -0.009 pp | 0.00% 0.000 pp | USD15.17 +15.3% | 22 qtrs — |
| 77 | DNB ASSET MANAGEMENT AS | 61.1K +30.1K (+97.5%) | 1.07M +429.1K (+67.2%) | 0.01% +0.004 pp | 0.00% +0.001 pp | USD19.30 -9.4% | 6 qtrs — |
| 78 | AQUATIC CAPITAL MANAGEMENT LLC | 59.9K +59.9K (+100.0%) | 1.05M +1.0M (+100.0%) | 0.01% +0.008 pp | 0.03% +0.030 pp | USD17.49 +0.0% | 1 qtrs NEW |
| 79 | ASSENAGON ASSET MANAGEMENT S.A. | 59.6K +59.6K (+100.0%) | 1.04M +1.0M (+100.0%) | 0.01% +0.008 pp | 0.00% +0.001 pp | USD17.49 +0.0% | 1 qtrs NEW |
| 80 | WEALTH MANAGEMENT PARTNERS, LLC | 59.4K -15.1K (-20.3%) | 1.04M -501.2K (-32.5%) | 0.01% -0.002 pp | 0.30% -0.193 pp | USD13.60 +28.6% | 9 qtrs — |
| 81 | FARTHER FINANCE ADVISORS, LLC | 57.3K +2.0K (+3.7%) | 1.00M -139.3K (-12.2%) | 0.01% +0.000 pp | 0.01% -0.007 pp | USD20.55 -14.9% | 2 qtrs — |
| 82 | AMERIPRISE FINANCIAL INC | 54.0K +500.0 (+0.9%) | 944.7K -160.9K (-14.6%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD19.33 -9.5% | 5 qtrs — |
| 83 | NEW YORK STATE COMMON RETIREMENT FUND | 53.8K -210.5K (-79.7%) | 940.6K -4.5M (-82.8%) | 0.01% -0.028 pp | 0.00% -0.006 pp | USD19.44 -10.0% | 11 qtrs — |
| 84 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 52.6K +114.0 (+0.2%) | 920.3K -164.4K (-15.2%) | 0.01% +0.000 pp | 0.01% -0.001 pp | USD19.88 -12.0% | 5 qtrs — |
| 85 | BALYASNY ASSET MANAGEMENT L.P. | 50.3K -144.6K (-74.2%) | 879.7K -3.1M (-78.1%) | 0.01% -0.020 pp | 0.00% -0.004 pp | USD20.66 -15.3% | 7 qtrs — |
| 86 | GUGGENHEIM CAPITAL LLC | 49.8K +8.8K (+21.5%) | 871.0K +24.0K (+2.8%) | 0.01% +0.001 pp | 0.01% +0.000 pp | USD18.16 -3.7% | 5 qtrs — |
| 87 | TREASURER OF THE STATE OF NORTH CAROLINA | 48.9K -3.6K (-6.8%) | 856.0K -229.0K (-21.1%) | 0.01% -0.001 pp | 0.00% -0.001 pp | USD21.28 -17.8% | 3 qtrs — |
| 88 | WORLDQUANT MILLENNIUM ADVISORS LLC | 41.7K +41.7K (+100.0%) | 729.9K +729.9K (+100.0%) | 0.01% +0.006 pp | 0.00% +0.003 pp | USD17.49 +0.0% | 1 qtrs NEW |
| 89 | BEACON POINTE ADVISORS, LLC | 39.6K +3.9K (+10.9%) | 692.8K -45.3K (-6.1%) | 0.01% +0.001 pp | 0.00% -0.001 pp | USD20.35 -14.1% | 2 qtrs — |
| 90 | MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | 38.0K +7.4K (+24.2%) | 664.5K +32.5K (+5.1%) | 0.01% +0.001 pp | 0.00% 0.000 pp | USD10.54 +65.9% | 12 qtrs — |
| 91 | LEVIN CAPITAL STRATEGIES, L.P. | 37.7K +1.0K (+2.7%) | 659.0K -98.8K (-13.0%) | 0.01% +0.000 pp | 0.06% -0.012 pp | USD6.43 +172.0% | 20 qtrs — |
| 92 | HANDELSBANKEN FONDER AB | 37.6K +3.4K (+9.9%) | 658.0K -49.0K (-6.9%) | 0.01% +0.001 pp | 0.00% 0.000 pp | USD12.41 +40.9% | 7 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 96 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | BMO Equal Weight US Health Care Hedged to CAD Index ETF ZUH.TO | 1.17% | 1.47M | 0.39% |
| 2 | Global X - S&P Biotech ETF CURE.AX | 1.05% | 378.4K | 0.45% |
| 3 | State Street SPDR S&P Biotech ETF XBI | 1.05% | 113.97M | 0.35% |
| 4 | Tema Oncology ETF CANC | 0.96% | 1.37M | 0.75% |
| 5 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.82% | 8.97M | 0.35% |
| 6 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.82% | 600.5K | 0.35% |
| 7 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.82% | 610.4K | 0.19% |
| 8 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.82% | 3.77M | 0.40% |
| 9 | Virtus Biotech Clinical Trials ETF BBC | 0.67% | 385.7K | 0.65% |
| 10 | ProShares Ultra Nasdaq Biotechnology BIB | 0.46% | 396.1K | 1.19% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
9
Sells
0
Shares acquired
29.16M
Shares disposed
—
Cash buys
3.00
Cash sales
—
Net activity
+29,162,212
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-08 | Anand Bhaskar | Officer | A-Award | A | Stock Option (right to buy) | 30,000 | 18.83 | 564.9K | 30,000 | D | ↗ |
| 2026-01-02 | Zanganeh Mahkam | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 11,232 | 17.52 | 196.8K | 11,232 | I | ↗ |
| 2026-01-02 | Xia Yu | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 17.52 | 613.2K | 35,000 | D | ↗ |
| 2026-01-02 | Ronaghi Mostafa | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 17.52 | 613.2K | 35,000 | D | ↗ |
| 2026-01-02 | Huber Jeff | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 17.52 | 613.2K | 35,000 | D | ↗ |
| 2026-01-02 | DUGGAN ROBERT W | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 11,232 | 17.52 | 196.8K | 11,232 | D | ↗ |
| 2026-01-02 | Clark Kenneth A | Director | A-Award | A | Stock Option (right to buy) | 17,796 | 17.52 | 311.8K | 17,796 | D | ↗ |
| 2026-01-02 | Cesano Alessandra | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 17.52 | 613.2K | 35,000 | D | ↗ |
| 2026-01-02 | Booth Robert F. | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 17.52 | 613.2K | 35,000 | D | ↗ |
| 2025-10-21 | Zanganeh Mahkam | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 26,680 | 18.74 | 500.0K | 76,680 | I | ↗ |
| 2025-10-21 | Xia Yu | Director | P-Purchase | A | Common Stock | 533,617 | 18.74 | 10.00M | 32,057,147 | I | ↗ |
| 2025-10-21 | Soni Manmeet Singh | Director / Officer | A-Award | A | Common Stock | 53,361 | 18.74 | 1,000.0K | 3,073,603 | D | ↗ |
| 2025-10-21 | DUGGAN ROBERT W | Director / Officer / 10% Owner | A-Award | A | Common Stock | 266,808 | 18.74 | 5.00M | 25,724,474 | I | ↗ |
| 2025-10-21 | Anand Bhaskar | Officer | A-Award | A | Common Stock | 26,680 | 18.74 | 500.0K | 159,751 | D | ↗ |
| 2025-09-18 | Anand Bhaskar | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 19.23 | 961.5K | 50,000 | D | ↗ |
| 2025-09-11 | Zanganeh Mahkam | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 5,000 | 18.07 | 90.4K | 556,093,090 | I | ↗ |
| 2025-09-11 | DUGGAN ROBERT W | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 5,000 | 18.07 | 90.4K | 556,093,090 | D | ↗ |
| 2025-09-10 | Zanganeh Mahkam | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 333,394 | 17.68 | 5.89M | 556,088,090 | I | ↗ |
| 2025-09-10 | DUGGAN ROBERT W | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 333,394 | 17.68 | 5.89M | 556,088,090 | D | ↗ |
| 2025-05-30 | Zanganeh Mahkam | Director / Officer / 10% Owner | M-Exempt | D | Stock Option (right to buy) | 74,545 | 2.64 | 196.8K | 0 | I | ↗ |
| 2025-05-30 | DUGGAN ROBERT W | Director / Officer / 10% Owner | M-Exempt | A | Common Stock | 74,545 | 2.64 | 196.8K | 555,754,696 | D | ↗ |
| 2025-04-29 | Zanganeh Mahkam | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 1,040,000 | 1.06 | 1.10M | 1,040,000 | D | ↗ |
| 2025-04-29 | Soni Manmeet Singh | Director / Officer | A-Award | A | Stock Option (right to buy) | 11,200,000 | 1.68 | 18.82M | 11,200,000 | D | ↗ |
| 2025-04-29 | DUGGAN ROBERT W | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 1,040,000 | 1.06 | 1.10M | 1,040,000 | I | ↗ |
| 2025-04-29 | Anand Bhaskar | Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 17.85 | 1.34M | 75,000 | D | ↗ |
| 2025-04-08 | Zanganeh Mahkam | Director / Officer / 10% Owner | X-InTheMoney | A | Common Stock | 3,985,055 | 1.58 | 6.30M | 555,680,151 | I | ↗ |
| 2025-04-08 | DUGGAN ROBERT W | Director / Officer / 10% Owner | X-InTheMoney | A | Common Stock | 3,985,055 | 1.58 | 6.30M | 555,680,151 | D | ↗ |
| 2025-01-12 | Anand Bhaskar | Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 17.85 | 1.34M | 75,000 | D | ↗ |
| 2025-01-02 | Zanganeh Mahkam | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 10,724 | 18.35 | 196.8K | 10,724 | I | ↗ |
| 2025-01-02 | Xia Yu | Director | A-Award | A | Stock Option (right to buy) | 5,438 | 18.35 | 99.8K | 5,438 | D | ↗ |
| 2025-01-02 | Ronaghi Mostafa | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 18.35 | 642.3K | 35,000 | D | ↗ |
| 2025-01-02 | Huber Jeff | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 18.35 | 642.3K | 35,000 | D | ↗ |
| 2025-01-02 | DUGGAN ROBERT W | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 10,724 | 18.35 | 196.8K | 10,724 | D | ↗ |
| 2025-01-02 | Clark Kenneth A | Director | A-Award | A | Stock Option (right to buy) | 16,991 | 18.35 | 311.8K | 16,991 | D | ↗ |
| 2025-01-02 | Cesano Alessandra | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 18.35 | 642.3K | 35,000 | D | ↗ |
| 2025-01-02 | Booth Robert F. | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 18.35 | 642.3K | 35,000 | D | ↗ |
| 2024-10-11 | Clark Kenneth A | Director | A-Award | A | Stock Option (right to buy) | 200,000 | 19.95 | 3.99M | 200,000 | D | ↗ |
| 2024-10-03 | Zanganeh Mahkam | Director / Officer | X-InTheMoney | A | Common Stock | 315,681 | 1.58 | 498.8K | 10,199,776 | I | ↗ |
| 2024-09-11 | Zanganeh Mahkam | Director / Officer | A-Award | A | Common Stock | 44,052 | 22.70 | 1,000.0K | 24,967,852 | — | ↗ |
| 2024-09-11 | Soni Manmeet Singh | Director / Officer | A-Award | A | Common Stock | 44,052 | 22.70 | 1,000.0K | 3,020,242 | — | ↗ |
| 2024-09-11 | Huber Jeff | Director | A-Award | A | Common Stock | 44,052 | 22.70 | 1,000.0K | 44,052 | — | ↗ |
| 2024-09-11 | DUGGAN ROBERT W | Director / Officer / 10% Owner | A-Award | A | Common Stock | 3,325,991 | 22.70 | 75.50M | 551,695,096 | — | ↗ |
| 2024-09-11 | Anand Bhaskar | Officer | A-Award | A | Common Stock | 22,026 | 22.70 | 500.0K | 131,426 | — | ↗ |
| 2024-08-23 | Zanganeh Mahkam | Director / Officer | A-Award | A | Performance Stock Option (right to buy) | 2,397,640 | 1.68 | 4.03M | 2,397,640 | — | ↗ |
| 2024-08-23 | Soni Manmeet Singh | Director / Officer | A-Award | A | Performance Stock Option (right to buy) | 2,800,000 | 1.68 | 4.70M | 2,800,000 | — | ↗ |
| 2024-06-27 | Huber Jeff | Director | A-Award | A | Stock Option (right to buy) | 17,883 | 7.87 | 140.7K | 217,883 | — | ↗ |
| 2024-04-11 | Ronaghi Mostafa | Director | A-Award | A | Stock Option (right to buy) | 25,315 | 4.03 | 102.0K | 225,315 | — | ↗ |
| 2024-04-02 | Soni Manmeet Singh | Director / Officer | A-Award | A | Stock Option (right to buy) | 1,100,000 | 3.85 | 4.24M | 1,100,000 | — | ↗ |
| 2024-04-02 | Anand Bhaskar | Officer | A-Award | A | Stock Option (right to buy) | 600,000 | 3.85 | 2.31M | 600,000 | — | ↗ |
| 2024-03-27 | Zanganeh Mahkam | Director / Officer | P-Purchase | A | Common Stock | 20,000 | 3.71 | 74.2K | 50,000 | — | ↗ |
| 2024-03-26 | Zanganeh Mahkam | Director / Officer | P-Purchase | A | Common Stock | 30,000 | 3.75 | 112.5K | 30,000 | — | ↗ |
| 2024-03-26 | Dhingra Ankur | Officer | P-Purchase | A | Common Stock | 100,000 | 3.75 | 375.0K | 354,958 | — | ↗ |
| 2024-01-02 | Xia Yu | Director | A-Award | A | Stock Option (right to buy) | 200,000 | 2.64 | 528.0K | 235,000 | — | ↗ |
| 2024-01-02 | Mahatme Ujwala | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 2.64 | 92.4K | 35,000 | — | ↗ |
| 2024-01-02 | DUGGAN ROBERT W | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 74,545 | 2.64 | 196.8K | 74,545 | — | ↗ |
| 2024-01-02 | Clark Kenneth A | Director | A-Award | A | Stock Option (right to buy) | 70,492 | 2.64 | 186.1K | 105,492 | — | ↗ |
| 2024-01-02 | Cesano Alessandra | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 2.64 | 92.4K | 35,000 | — | ↗ |
| 2024-01-02 | Booth Robert F. | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 2.64 | 92.4K | 35,000 | — | ↗ |
| 2023-12-31 | Xia Yu | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-12-13 | Dhingra Ankur | Officer | P-Purchase | A | Common Stock | 700 | 2.15 | 1.5K | 235,258 | — | ↗ |
| 2023-12-12 | Zanganeh Mahkam | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 2.07 | 10.4K | 494,814 | — | ↗ |
| 2023-12-11 | Zanganeh Mahkam | Director / Officer | X-InTheMoney | D | Warrant (right to buy) | 489,814 | 1.44 | 705.3K | 0 | — | ↗ |
| 2023-10-13 | Zanganeh Mahkam | Director / Officer | A-Award | A | Stock Option (right to buy) | 11,988,198 | 1.68 | 20.14M | 11,988,198 | — | ↗ |
| 2023-10-13 | Soni Manmeet Singh | Director / Officer | A-Award | A | Stock Option (right to buy) | 14,000,000 | 1.68 | 23.52M | 14,000,000 | — | ↗ |
| 2023-03-08 | Zanganeh Mahkam | Director / Officer | P-Purchase | A | Common Stock | 804,672 | 1.05 | 844.9K | 1,178,529 | — | ↗ |
| 2023-03-07 | Dhingra Ankur | Officer | P-Purchase | A | Common Stock | 196,362 | 1.05 | 206.2K | 234,558 | — | ↗ |
| 2023-03-06 | DUGGAN ROBERT W | Director / Officer | P-Purchase | A | Common Stock | 376,489,880 | 1.05 | 395.31M | 552,354,161 | — | ↗ |
| 2023-01-17 | Xia Yu | — | — | — | — | — | — | — | 0 | — | ↗ |
| 2023-01-03 | Soni Manmeet Singh | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 0.00 | — | 35,000 | — | ↗ |
| 2023-01-03 | Mahatme Ujwala | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 0.00 | — | 35,000 | — | ↗ |
| 2023-01-03 | Clark Kenneth A | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 0.00 | — | 35,000 | — | ↗ |
| 2023-01-03 | Cesano Alessandra | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 0.00 | — | 35,000 | — | ↗ |
| 2023-01-03 | Booth Robert F. | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 0.00 | — | 35,000 | — | ↗ |
| 2022-12-06 | Zanganeh Mahkam | Officer | J-Other | A | Common Stock | 373,857 | 0.00 | — | 10,930,849 | — | ↗ |
| 2022-12-06 | DUGGAN ROBERT W | Officer | J-Other | A | Common Stock | 9,346,434 | 0.00 | — | 171,879,226 | — | ↗ |
| 2022-11-15 | Cesano Alessandra | Director | A-Award | A | Stock Option (right to buy) | 4,166 | 0.00 | — | 204,166 | — | ↗ |
| 2022-09-28 | Booth Robert F. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-08-16 | Zanganeh Maky | Officer | P-Purchase | A | Common Stock | 1,030,925 | 0.97 | 1,000.0K | 3,135,466 | — | ↗ |
| 2022-08-16 | Dhingra Ankur | Officer | P-Purchase | A | Common Stock | 11,557 | 0.97 | 11.2K | 38,057 | — | ↗ |
| 2022-08-16 | DUGGAN ROBERT W | Officer | P-Purchase | A | Common Stock | 94,849,203 | 0.97 | 92.00M | 162,532,792 | — | ↗ |
| 2022-06-01 | Maranian Jeffrey R | Officer | — | D | Stock Option (right to buy) | 20,000 | 6.61 | 132.2K | 0 | — | ↗ |
| 2022-05-31 | Dhingra Ankur | Officer | — | D | Common Stock | 0 | 0.00 | — | 26,500 | — | ↗ |
| 2022-05-23 | DUGGAN ROBERT W | Officer | J-Other | A | Common Stock | 21,135 | 0.00 | — | 67,683,589 | — | ↗ |
| 2022-04-25 | Gayko Urte | Director | A-Award | A | Stock Option (right to buy) | 400,000 | 0.00 | — | 400,000 | — | ↗ |
| 2022-01-03 | Soni Manmeet Singh | Director | A-Award | A | Stock Option (right to buy) | 82,446 | 2.82 | 232.5K | 107,446 | — | ↗ |
| 2022-01-03 | Mahatme Ujwala | Director | A-Award | A | Stock Option (right to buy) | 47,872 | 2.82 | 135.0K | 72,872 | — | ↗ |
| 2022-01-03 | Gayko Urte | Director | A-Award | A | Stock Option (right to buy) | 42,553 | 2.82 | 120.0K | 67,553 | — | ↗ |
| 2022-01-03 | Clark Kenneth A | Director | A-Award | A | Stock Option (right to buy) | 58,510 | 2.82 | 165.0K | 83,510 | — | ↗ |
| 2021-12-15 | Zanganeh Maky | Director / Officer | A-Award | A | Stock Option (right to buy) | 15,000 | 4.75 | 71.3K | 15,000 | — | ↗ |
| 2021-12-15 | Maranian Jeffrey R | Officer | A-Award | A | Stock Option (right to buy) | 15,000 | 4.75 | 71.3K | 15,000 | — | ↗ |
| 2021-11-22 | Maranian Jeffrey R | Officer | — | D | Stock Option (right to buy) | 112,500 | 4.40 | 495.0K | 0 | — | ↗ |
| 2021-11-11 | Maranian Jeffrey R | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 5.28 | 264.0K | 50,000 | — | ↗ |
| 2021-11-03 | Gayko Urte | Director | A-Award | A | Stock Option (right to buy) | 4,041 | 5.54 | 22.4K | 204,041 | — | ↗ |
| 2021-10-07 | Clark Kenneth A | Director | A-Award | A | Stock Option (right to buy) | 6,250 | 5.03 | 31.4K | 206,250 | — | ↗ |
| 2021-05-12 | Zanganeh Maky | Director / Officer | P-Purchase | A | Common Stock | 389,077 | 5.24 | 2.04M | 2,643,319 | — | ↗ |
| 2021-05-12 | DUGGAN ROBERT W | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 11,365,921 | 5.24 | 59.56M | 67,662,454 | — | ↗ |
| 2021-02-28 | Wang Luhua | Director | A-Award | A | Stock Option (right to buy) | 21,096 | 6.77 | 142.8K | 91,096 | — | ↗ |
| 2021-02-26 | Wang Luhua | Director | A-Award | A | Stock Option (right to buy) | 70,000 | 6.77 | 473.9K | 70,000 | — | ↗ |
| 2021-02-19 | Soni Manmeet Singh | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 7.33 | 183.3K | 252,273 | — | ↗ |
| 2021-02-19 | Mahatme Ujwala | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 7.33 | 183.3K | 238,340 | — | ↗ |
| 2021-02-19 | Erdtmann Rainer M | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 7.33 | 183.3K | 252,273 | — | ↗ |
| 2021-02-19 | Donaldson Michael Paul | Officer | D-Return | D | Stock Option (right to buy) | 5,110 | 3.52 | 18.0K | 594,890 | — | ↗ |
| 2020-11-30 | Powell David Jonathan | Officer | S-Sale | D | Common Stock | 13,713 | 4.44 | 60.9K | 0 | — | ↗ |
| 2020-11-27 | Powell David Jonathan | Officer | M-Exempt | A | Common Stock | 16,616 | 1.92 | 31.9K | 16,616 | — | ↗ |
| 2020-11-25 | Powell David Jonathan | Officer | M-Exempt | A | Common Stock | 12,070 | 1.92 | 23.2K | 12,070 | — | ↗ |
| 2020-11-24 | Powell David Jonathan | Officer | S-Sale | D | Common Stock | 11,374 | 4.21 | 47.9K | 0 | — | ↗ |
| 2020-11-23 | Powell David Jonathan | Officer | S-Sale | D | Common Stock | 6,987 | 4.40 | 30.7K | 0 | — | ↗ |
| 2020-11-22 | Zanganeh Maky | Director / Officer | A-Award | A | Stock Option (right to buy) | 2,400,000 | 4.40 | 10.56M | 3,724,499 | — | ↗ |
| 2020-11-11 | Zanganeh Maky | Director | — | I | Common Stock | 0 | 0.00 | — | 2,254,242 | — | ↗ |
| 2020-11-06 | DUGGAN ROBERT W | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 14,071,856 | 3.34 | 47.00M | 56,296,533 | — | ↗ |
| 2020-10-04 | Graham Camilla | Officer | A-Award | A | Stock Option (right to buy) | 400,000 | 3.34 | 1.34M | 400,000 | — | ↗ |
| 2020-10-02 | DUGGAN ROBERT W | Director / Officer / 10% Owner | A-Award | A | Common Stock | 9,730,539 | 3.34 | 32.50M | 9,730,539 | — | ↗ |
| 2020-09-18 | Stefanov Ventzislav | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 14,900 | — | ↗ |
| 2020-09-18 | Soni Manmeet Singh | Director | — | D | Stock Option (right to buy) | 200,000 | 1.37 | 274.0K | 0 | — | ↗ |
| 2020-09-18 | Powell David Jonathan | Officer | — | D | Stock Option (right to buy) | 84,686 | 1.92 | 162.6K | 0 | — | ↗ |
| 2020-09-18 | Houbiers Jos | Officer | — | D | Stock Option (right to buy) | 20,000 | 3.17 | 63.4K | 0 | — | ↗ |
| 2020-09-18 | Erdtmann Rainer M | Director | — | D | Stock Option (right to buy) | 27,273 | 3.30 | 90.0K | 0 | — | ↗ |
| 2020-09-18 | Donaldson Michael Paul | Officer | — | D | Stock Option (right to buy) | 600,000 | 3.52 | 2.11M | 0 | — | ↗ |
| 2020-09-18 | DUGGAN ROBERT W | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 42,224,677 | — | ↗ |
| 2020-06-30 | Zanganeh Maky | Director | — | D | Warrant (right to buy) | 489,815 | 1.44 | 705.3K | 0 | — | ↗ |
| 2020-06-24 | Zanganeh Maky | Director | — | I | Warrant (right to buy) | 315,681 | 1.58 | 498.8K | 0 | — | ↗ |
| 2020-06-24 | DUGGAN ROBERT W | Director / Officer / 10% Owner | — | D | Warrant (right to buy) | 3,985,055 | 1.58 | 6.30M | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
775.37M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Manmeet Soni, Chief Operating Officer, Chief Financial Officer and Director | 616.5K | 388.4K | — | 248.10M | — | 21.0K | 249.13M | 99.59% | ↗ |
| 2 | 2025 | Mahkam Zanganeh, Co-Chief Executive Officer, President and Director | 616.5K | 388.4K | — | 245.02M | — | 21.0K | 246.05M | 99.58% | ↗ |
| 3 | 2025 | Robert W. Duggan, Co-Chief Executive Officer and Chairman | — | — | — | — | — | 172.4K | 172.4K | 0.00% | ↗ |
| 4 | 2024 | Manmeet Soni, Chief Operating Officer, Chief Financial Officer and Director | 600.0K | 640.0K | — | 3.51M | — | 21.0K | 4.77M | 73.58% | ↗ |
| 5 | 2024 | Mahkam Zanganeh, Co-Chief Executive Officer, President and Director | 600.0K | 540.0K | — | — | — | 21.0K | 1.16M | 0.00% | ↗ |
| 6 | 2024 | Ankur Dhingra, Former Chief Financial Officer | 144.2K | 91.3K | — | — | — | 20.8K | 256.3K | 0.00% | ↗ |
| 7 | 2024 | Robert W. Duggan, Co-Chief Executive Officer and Chairman | — | — | — | — | — | 158.6K | 158.6K | 0.00% | ↗ |
| 8 | 2023 | Manmeet Soni, Chief Operating Officer and Chief Financial Officer | 100.0K | — | — | 23.38M | — | 131.7K | 23.61M | 99.02% | ↗ |
| 9 | 2023 | Manmeet Soni, Chief Operating Officer, Chief Financial Officer and Director | 100.0K | — | — | 23.38M | — | 131.7K | 23.61M | 99.02% | ↗ |
| 10 | 2023 | Mahkam Zanganeh, Co-Chief Executive Officer, President and Director | 600.0K | — | — | 19.91M | — | 57.8K | 20.56M | 96.80% | ↗ |
| 11 | 2023 | Mahkam Zanganeh, Director, Chief Executive Officer, and President | 600.0K | — | — | 19.91M | — | 57.8K | 20.56M | 96.80% | ↗ |
| 12 | 2023 | Ankur Dhingra, Former Chief Financial Officer | 500.0K | 91.3K | — | — | — | 30.0K | 621.3K | 0.00% | ↗ |
| 13 | 2022 | Ankur Dhingra, Chief Financial Officer | 264.2K | 381.9K | — | 694.5K | — | 22.2K | 1.36M | 50.96% | ↗ |
| 14 | 2022 | Ankur Dhingra, Former Chief Financial Officer | 264.2K | 381.9K | — | 694.5K | — | 22.2K | 1.36M | 50.96% | ↗ |
| 15 | 2022 | Mahkam Zanganeh, Director, co-Chief Executive Officer, and President | 450.0K | 452.5K | — | 307.2K | — | 32.3K | 1.24M | 24.73% | ↗ |
| 16 | 2022 | Mahkam Zanganeh, Co-Chief Executive Officer, President and Director | 450.0K | 452.5K | — | 307.2K | — | 32.3K | 1.24M | 24.73% | ↗ |
| 17 | 2022 | Mahkam Zanganeh, Director, Chief Executive Officer, and President | 450.0K | 452.5K | — | 307.2K | — | 32.3K | 1.24M | 24.73% | ↗ |
| 18 | 2021 | Mahkam Zanganeh, Director and Chief Operations Officer | 450.0K | 182.3K | — | 8.99M | — | 19.2K | 9.64M | 93.24% | ↗ |
| 19 | 2021 | Mahkam Zanganeh, Director, co-Chief Executive Officer, and President | 450.0K | 182.3K | — | 8.99M | — | 19.2K | 9.64M | 93.24% | ↗ |
| 20 | 2021 | Mahkam Zanganeh, Director, Chief Executive Officer, and President | 450.0K | 182.3K | — | 8.99M | — | 19.2K | 9.64M | 93.24% | ↗ |
| 21 | 2021 | David Powell, Former Chief Scientific Officer | 288.5K | — | — | 1.24M | — | 75.8K | 1.61M | 77.33% | ↗ |
| 22 | 2021 | Jeffrey Maranian, Principal Accounting Officer | 289.6K | — | — | 707.1K | — | 47.5K | 1.04M | 67.72% | ↗ |
| 23 | 2020 | Michael Donaldson, Chief Financial Officer | 206.7K | 79.9K | — | 665.2K | — | 9.6K | 961.4K | 69.19% | ↗ |
| 24 | 2020 | Ventzislav Stefanov, Former Executive Vice President, President of Discuva and Director | 290.7K | — | — | 277.5K | — | 106.6K | 674.8K | 41.12% | ↗ |
| 25 | 2020 | Glyn Edwards, Former Chief Executive Officer and Director | 137.9K | 3.2K | — | — | — | 480.7K | 621.8K | 0.00% | ↗ |
| 26 | 2020 | Mahkam Zanganeh, Director and Chief Operations Officer | 49.6K | — | — | 476.3K | — | 1.4K | 527.3K | 90.33% | ↗ |
| 27 | 2020 | Mahkam Zanganeh, Director, co-Chief Executive Officer, and President | 49.6K | — | — | 476.3K | — | 1.4K | 527.3K | 90.33% | ↗ |
| 28 | 2020 | Mahkam Zanganeh, Director and Chief Operating Officer | 49.6K | — | — | 476.3K | — | 1.4K | 527.3K | 90.33% | ↗ |
| 29 | 2020 | David Powell, Former Chief Scientific Officer | 266.9K | 46.8K | — | — | — | 87.4K | 401.1K | 0.00% | ↗ |
| 30 | 2019 | Glyn Edwards, Former Chief Executive Officer and Director | 378.1K | 2.6K | — | 459.3K | — | 31.9K | 871.9K | 52.68% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Mahkam Zanganeh | Co-CEO, President & Director | 1M | — |
| Manmeet Singh Soni | Chief Operating Officer, Chief Financial Officer & Director | 1M | male |
| Robert W. Duggan | Co-CEO & Executive Chairman | 172.4K | male |
| Fong Clow | Chief Biometrics Officer | — | — |
| Kay Elizabeth Davies | Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor | — | — |
| Laura Q. Chow | Senior Vice President of Clinical Development | — | — |
| Nathan LiaBraaten | Senior Director of Investor Relations | — | male |
| Robert LaCaze | Chief Commercial Officer | — | male |
| Urte Gayko | Chief Regulatory, Quality & Pharmacovigilance Officer | — | — |
| Allen S. Yang | Head of R&D Strategy | — | — |
| Wang Clow Fong | Chief Biometrics Officer | — | — |
| Bhaskar Anand | Chief Accounting Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SMMT
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
